<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-109
Date of Submission: 2025-02-19

This report was submitted by a Other Healthcare Professional from Jones LLC Medical Center concerning patient ANON-PX-3290. The subject is a 21-year-old male with a significant medical history including coronary artery disease, atrial fibrillation, asthma, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin administered via the Oral route at a dosage of 373mg, initiated on 2024-12-30 for Neuropathic pain and discontinued on 2025-02-18; Metformin (Biguanide) administered via the Subcutaneous route at a dosage of 375mg, initiated on 2024-12-30 for Type 2 diabetes and discontinued on 2025-02-18.

On approximately 2025-02-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Somnolence. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed three and advised our. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Yeah community worker collection. Account usually public wear art Mr plant drop. Such human teach feel cover.</data>
report_id: ADR-2025-109
report_date: '2025-02-19'
patient_details:
  patient_id: ANON-PX-3290
  gender: Male
  relevant_history:
  - coronary artery disease
  - atrial fibrillation
  - asthma
  - chronic kidney disease
  age_at_reaction: 21
suspected_drugs:
- drug_name: Gabapentin
  dosage: 373mg
  route_of_administration: Oral
  start_date: '2024-12-30'
  indication_for_use: Neuropathic pain
  end_date: '2025-02-18'
- drug_name: Metformin
  dosage: 375mg
  route_of_administration: Subcutaneous
  start_date: '2024-12-30'
  indication_for_use: Type 2 diabetes
  drug_class: Biguanide
  end_date: '2025-02-18'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2025-02-10'
  severity: Moderate
  outcome: Recovered
  intervention_required: true
- symptom_name: Somnolence
  onset_date: '2025-02-10'
  severity: Severe
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed three and advised our.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 3
reporting_facility: Jones LLC Medical Center
reporter_type: Other Healthcare Professional
notes: Yeah community worker collection. Account usually public wear art Mr plant
  drop. Such human teach feel cover.
